Integrating biologic therapy into the comprehensive care of patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue SUPPL. 72, 2005, Pages 54-57

  Lipsky, Peter E ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Biologic therapy; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

BIOLOGICAL THERAPY; CONFERENCE PAPER; DISEASE COURSE; DRUG COST; FUTUROLOGY; GENETIC PREDISPOSITION; HEALTH CARE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOGRAPHY; RHEUMATOID ARTHRITIS; METHODOLOGY; PATHOLOGY; REVIEW;

ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COMPREHENSIVE HEALTH CARE; HUMANS;

EID: 11344277297     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Wolfe F, Hawley D. The long-term outcomes of rheumatoid arthritis: Work disability: A prospective 18-year study of 823 patients. J Rheumatol 1998;25:2108-17.
2. Drossaers-Bakker KW, Zwinderman AH, Vlieland TP, et al. Long-term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002;47:383-90.
3. Kavanaugh A, Lipsky PE. Biologics in the treatment of rheumatoid arthritis: Mechanisms of action. In: Goronzy JJ, Weyand CM, editors. Rheumatoid arthritis. Vol. 3. Basel: Karger; 2001:240-73.
4. Goldbach-Mansky R, Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 2003;54:197-216.
5. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
6. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
7. Weinblatt WE, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
8. Weinblatt WE, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA Trial. Arthritis Rheum 2003;48:35-45.
9. Bresnihan B, Keystone EC, Furst DE, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
10. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
11. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologie progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
12. Barton A, Ollier W. Genetic approaches to the investigation of rheumatoid arthritis. Curr Opin Rheumatol 2002;14:260-9.
13. Gregersen PK. Teasing apart the complex genetics of human autoimmunity: lessons from rheumatoid arthritis. Clin Immunol 2003;107:1-9.
14. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835-41.
15. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5.
16. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8.
17. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12.
18. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-84.
19. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-6.